title: Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
abstract: OBJECTIVE
  Romidepsin is a histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma (CTCL). Durable responses have been published without establishing a standard recommendation about duration of treatment.
  
  
  OBJECTIVE
  To review the long-term use of romidepsin in responders who received a dose-sparing regimen.
  
  
  METHODS
  Retrospective review of medical records of patients with a diagnosis of CTCL, including mycosis fungoides (MF), Sézary syndrome (SS), or CTCL not otherwise specified seen at a multidisciplinary clinic at Northwestern University from 2009 until December 2014.
  
  
  METHODS
  Doses administered and different regimens of romidepsin were reviewed.
  
  
  METHODS
  Duration of treatment, participants receiving dose-sparing regimen.
  
  
  RESULTS
  Of 47 patients identified, 23 had MF, 15 had SS, and 9 had other types of CTCL. None of these 9 (mostly cytotoxic lymphomas) achieved a durable response. Of the remaining 38 patients, 17 were considered long-term responders (>6 months of treatment). Nine of these patients received a dose-sparing regimen. The median (range) duration of treatment was 15 (7-34) months; the frequency of patients with SS (10 of 15) in the long-term group was significantly higher than that of patients with MF (7 of 23; P = .046). Adverse events were reported in 29 (69%) of 42 patients for whom data were available. There was no significant difference in the incidence of AEs between the short-term and long-term groups (12 of 21 vs 12 of 17; P = .50).
  
  
  CONCLUSIONS
  Decreasing the frequency of infusions in patients with MF or SS who achieve a response with romidepsin therapy may provide a practical strategy to prolong response.
authors.affiliation: Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
authors.forename: M Estela
authors.initials: ME
authors.lastname: Martinez-Escala
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Kuzel
authors.affiliation: Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Jason B
authors.initials: JB
authors.lastname: Kaplan
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Adam
authors.initials: A
authors.lastname: Petrich
authors.affiliation: Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Nardone
authors.affiliation: Comprehensive Cancer Center and Beckman Research Institute, City of Hope, Duarte, California.
authors.forename: Steven T
authors.initials: ST
authors.lastname: Rosen
authors.affiliation: Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Joan
authors.initials: J
authors.lastname: Guitart
mesh_terms: D047630:Depsipeptides / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions / Q000145:classification / Q000473:pathology; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008499:Medical Records; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology
chemical_list: D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; C087123:romidepsin